MILD COGNITIVE IMPAIRMENT IN NEUROLOGICAL PRACTICE

Cognitive impairment and dementia are an relevant problem of modern neurology and psychiatry, which is explained by their wide prevalence, as well as the predicted increase in the number of patients in the future. However, dementia in most cases does not occur acutely, its development is preceded by a long period when cognitive impairments do not disrupt the patient’s everyday and professional life yet. Such cognitive impairments are called “pre-dementia” and are divided into subjective, subtle, and mild. With subjective cognitive impairment, patients present complaints; however, neuropsychological testing does not reveal decreased cognitive functions. Subtle cognitive impairment is accompanied by a decrease in cognitive functions when using highly sensitive scales. This article provides an overview of current data on the definition, classification, diagnosis, and treatment of mild cognitive impairment (MCI) from the point of view of the evidence-based medicine for timely diagnostics of the state and its effective correction. In patients with MCI, in addition to complaints of cognitive deficit, it is detected during screening neuropsychological testing; but unlike dementia, it does not impair the patient’s functionality. MCI is a leading risk factor for future dementia. However, according to research, cognitive deficits can not only progress, but also stabilize and even regress. In this regard, it is important to identify patients with MCI on time, establish nosological affiliation for correcting risk factors and prescribing treatment. The most common causes of MCI can be neurodegenerative disorders (primarily Alzheimer’s disease) and cerebrovascular diseases. The authors present the diagnostic value of popular scales such as the Mini-Mental State Examination, the Montreal Cognitive Assessment Scale and the 3-CT test in the diagnosis of MCI. The possibilities of using biomarkers, such as the determination of beta-amyloid and tau-protein in the cerebrospinal fluid, and the detection of signs of neuronal damage during neuroimaging of the brain, are discussed. It is stated that the most proven methods of influencing cognitive deficits in MCI are non-drug measures.

1. Prince M., Bryce R., Albanese E., et al. The global prevalence of dementia: A systematic review and metaanalysis // Alzheimer’s Dement. – 2013. – Vol. 9(1). – P. 63-75.e2. doi:10.1016/j.jalz.2012.11.007

2. Matthews F.E., Arthur A., Barnes L.E., et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: Results of the cognitive function and ageing study i and II // Lancet. – 2013. – Vol. 382(9902). – P. 1405-1412. doi:10.1016/S0140-6736(13)61570-6

3. Zakharov V.V., Novikova M.S., Vakhnina N.V. Prevention of dementia in patients with moderate cognitive impairment // Journal of Neurology and Psychiatry. S.S. Korsakov. – 2020. – Vol. 120 (8). – P. 167-174 (in Russ). doi:10.17116/jnevro2020120081167

4. Zakharov V.V., Kabaeva A.R. Non-dementia cognitive impairment: subtle, subjective, and mild // Nervous diseases. – 2017. – Vol. 4. – P. 3-9 (in Russ).

5. Knopman D.S., Gottesman R.F., Sharrett A.R., et al. Mild cognitive impairment and dementia prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study // Alzheimer’s Dement Diagnosis, Assess Dis Monit. – 2016. – Vol. 2. – P. 1-11. doi:10.1016/j.dadm.2015.12.002

6. Petersen R.C., Roberts R.O., Knopman D.S., et al. Prevalence of mild cognitive impairment is higher in men: The Mayo Clinic Study of Aging // Neurology. – 2010. – Vol. 75(10). – P. 889-897. doi:10.1212/WNL.0b013e3181f11d85

7. Overton M., Pihlsgård M., Elmståhl S. Prevalence and Incidence of Mild Cognitive Impairment across Subtypes, Age, and Sex // Dement Geriatr Cogn Disord. – 2019. – Vol. 47(4-6). – P. 219-232. doi:10.1159/000499763

8. Ganguli M., Chang C., Snitz B., et al. Prevalence of mild cognitive impairment by multiple classifications: The monongahela-youghiogheny healthy aging team (MYHAt) project // Am J Geriatr Psychiatry. – 2010. – Vol. 18(8). – P. 674-683. doi:10.1097/JGP.0b013e3181cdee4f

9. Di Carlo A., Lamassa M., Baldereschi M., et al. CIND and MCI in the Italian elderly // Neurology. – 2007. – Vol. 68(22). – P. 1909-1916.

10. Ganguli M., Snitz B.E., Saxton J.A., et al. Outcomes of Mild Cognitive Impairment by Definition // Arch Neurol. – 2011. – Vol. 68(6). – P. 761-767. doi:10.1001/archneurol.2011.101

11. Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease // Alzheimer’s Dement. – 2011. – Vol. 7(3). – P. 270-279. doi:10.1016/j.jalz.2011.03.008

12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. – 2013. doi:10.1176/appi.books.9780890425596.744053

13. Petersen R.C. Mild cognitive impairment as a diagnostic entity // J Intern Med. – 2004. – Vol. 256(3). – P. 183-194. doi:10.1111/j.1365-2796.2004.01388.x

14. Lokshina A.B., Zakharov V.V., Grishina D.A. et al. Heterogeneity of the syndrome of moderate cognitive impairment (analysis of the work of a specialized outpatient clinic) // Neurology, neuropsychiatry, psychosomatics. – 2021. – Vol. 13(3). – P. 34-41 (in Russ). doi:10.14412/2074-2711-2021-3-34-41

15. Levin O.S. Pre-dementia neurocognitive disorders in the elderly // S.S. Korsakov Journal of Neurology and Psychiatry. – 2019. – Vol. 119 (9). – P. 10-17 (in Russ). doi:10.17116/jnevro201911909210

16. Tang-Wai D.F., Knopman D.S., Geda Y.E., et al. Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment // Arch Neurol. –2003. – Vol. 60(12). – P. 1777. doi:10.1001/archneur.60.12.1777

17. Lancu I., Olmer A. The minimental state examination--an up-to-date review // Harefuah. – 2006. – Vol. 145(9). – P. 687-701. http://www.ncbi.nlm.nih.gov/pubmed/17078433

18. Starchina Yu.A. Non-demented cognitive impairments: a modern view of the problem // Neurology, neuropsychiatry, psychosomatics. – 2017. – Vol. 9 (2). – P. 71-76 (in Russ). doi:10.14412/2074-2711-2017-2-71-76

19. Ciesielska N., Sokołowski R., Mazur E., et al. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis // Psychiatr Pol. – 2016. – Vol. 50(5). – P. 1039-1052. doi:10.12740/pp/45368

20. Gutorova D.A., Vasenina E.E., Levin O.S. Screening for cognitive impairment in elderly and senile patients using the 3-CT scale // S.S. Korsakov Journal of Neurology and Psychiatry. – 2016. – Vol. 116 (Special issue 6). – P. 35-40 (in Russ). doi:10.17116/jnevro20161166235-40

21. Bogolepova A.N., Vasenina E.E., Gomzyakova N.A. et al. Clinical guidelines “Cognitive disorders in elderly and senile patients” // S.S. Korsakov Journal of Neurology and Psychiatry. – 2021. – Vol. 121(10). – 141 p. (in Russ). doi:10.17116/jnevro20211211036

22. Petersen R.C., Lopez O., Armstrong M.J., et al. Practice guideline update summary: Mild cognitive impairment report of theguideline development, dissemination, and implementation // Neurology. – 2018. – Vol. 90(3). – P. 126-135. doi:10.1212/WNL.0000000000004826

23. Levin O.S., Yunischenko N.A., Dudarova M.A. The effectiveness of akatinol memantine in moderate cognitive impairment // S.S. Korsakov Journal of Neurology and Psychiatry. – 2010. – Vol. 109 (7). – P. 36-42 (in Russ).

24. Uspenskaya O.V., Yakhno N.N. Influence of memantine on the cognitive functions of patients with an amnestic variant of the syndrome of moderate cognitive impairment (clinical-psychological and neurochemical study) // Neurological journal. – 2009. – Vol. 14 (9). – P. 37-40 (in Russ).

25. Yakhno N.N., Preobrazhenskaya I.S., Zakharov V.V., Mkhitaryan E.A. Efficacy of akatinol memantine in patients with non-dementia cognitive disorders. Results of multicenter clinical observation // Russian neurological journal. – 2019. – Vol. 3. – P. 37-44 (in Russ). doi:10.30629/2658-7947-2019-24-3-37-44

26. Levin O.S. Moderate cognitive impairment: diagnosis and treatment // Effective pharmacotherapy. – 2012. – Vol. 5. – P. 14-20 (in Russ).

27. Zakharov V.V. All-Russian Program for Research on the Epidemiology and Therapy of Cognitive Disorders in the Elderly (“PROMETHEUS”) // Neurological Journal. – 2006. – Vol. 11. – P. 27-32 (in Russ).

28. Yakhno N.N., Zakharov V.V., Strachunskaya E. Ya. et al. Treatment of non-demented cognitive impairment in patients with arterial hypertension and cerebral atherosclerosis (according to the Russian multicenter study “Fuete”) // Neurological journal. – 2012. – Vol. 17(4). – P. 49-55 (in Russ).

29. Stage E., Svaldi D., Sokolow S., et al. Prescribing cholinesterase inhibitors in mild cognitive impairment— Observations from the Alzheimer’s Disease Neuroimaging Initiative // Alzheimer’s Dement Transl Res Clin Interv. – 2021. – Vol. 7(1). – P. 1-11. doi:10.1002/trc2.12168

30. Winblad B., Gauthier S., Scinto L., et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment // Neurology. – 2008. – Vol. 70(22). – P. 2024-2035. doi:10.1212/01.wnl.0000303815.69777.26

31. Doody R.S., Ferris S.H., Salloway S., et al. Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial // Neurology. – 2009. – Vol. 72(18). – P. 1555-1561. doi:10.1212/01.wnl.0000344650.95823.03

32. Preobrazhenskaya I.S., Fantalis D., Abdyshova S.A., Kindarova A.A. Non-drug methods of therapy for cognitive impairment // Neurology, neuropsychiatry, psychosomatics. – 2019. – Vol. 11 (App. 3). – P. 68-77 (in Russ). doi:10.14412/2074-2711-2019-3S-68-77

33. Hill N., Mowszowski L., Naismith S., et al. Computerized cognitive training in older adults with mild cognitive impairment or dementia: A systematic review and meta-analysis // Am J Psychiatry. – 2017. – Vol. 174(4). – P. 329-340. doi:10.1176/appi.ajp.2016.16030360

34. Ge S., Zhu Z., Wu B., McConnell E.S. Technology-based cognitive training and rehabilitation interventions for individuals with mild cognitive impairment: A systematic review // BMC Geriatr. – 2018. – Vol. 18(1). doi:10.1186/s12877-018-0893-1

35. Lautenschlager N.T., Cox K.L., Flicker L., et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: A randomized trial // JAMA - J Am Med Assoc. – 2008. – Vol. 300(9). – P. 1027-1037. doi:10.1001/jama.300.9.1027

36. Karssemeijer E., Aaronson J., Bossers W., et al. Positive effects of combined cognitive and physical exercise training on cognitive function in older adults with mild cognitive impairment or dementia: A metaanalysis // Ageing Res Rev. – 2017. – Vol. 40. – P. 75-83. doi:10.1016/j.arr.2017.09.003

37. Roberts R.O., Geda Y.E., Cerhan J.R., et al. Vegetables, unsaturated fats, moderate alcohol intake, and mild cognitive impairment // Dement Geriatr Cogn Disord. – 2010. – Vol. 29(5). – P. 413-423. doi:10.1159/000305099